Literature DB >> 3905370

Molecular conformation, receptor binding, and hormone action of natural and synthetic estrogens and antiestrogens.

W L Duax, J F Griffin, C M Weeks, K S Korach.   

Abstract

The X-ray crystallographic structural determinations of synthetic estrogens and antiestrogens provide reliable information on the global minimum energy conformation of these molecules or a local minimum energy conformation that is within 1 or 2 kcal/mole of the global minimum. In favorable cases, state-of-the-art molecular mechanics calculations provide quantitative agreement with X-ray results and information on the relative energy of other local minimum energy conformations not observed crystallographically. Because the conformation of diethylstilbestrol (DES) observed in solvated crystals has an overall conformation and dipole moment more similar to estradiol it is the form more likely to bind to the receptor and produce hormone activity. Either phenol ring of DES can successfully mimic the estradiol A-ring in binding to the receptor. Indenestrol A (INDA) and indenestrol B (INDB) have nearly identical fully extended planar conformations. Either the alpha or gamma rings of these compounds may mimic the A ring of estradiol and compete for the estrogen receptor. Although there are eight distinct ways in which molecules of a racemic mixture of INDA or INDB can bind to the receptor, not all of them may be able to elicit a hormonal response. This may account for the reduced biological activity of the compounds despite their successful competition for receptor binding. The minimum energy conformations of Z-pseudodiethylstilbestrol (ZPD) and E-pseudodiethylstilbestrol (EPD) are bent in a fashion similar to that of indanestrol (INDC). These molecules have good binding affinity suggesting that the receptor does not require a flat molecule. Therefore these conformations would appear to be compatible with receptor binding, but only the Z isomer has an energetically allowed extended conformation that accounts for its observed biological activity relative to DES.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3905370      PMCID: PMC1568768          DOI: 10.1289/ehp.8561111

Source DB:  PubMed          Journal:  Environ Health Perspect        ISSN: 0091-6765            Impact factor:   9.031


  7 in total

1.  A series of optical structural and isomeric analogs of estradiol: a comparative study of the biological activity and affinity to cytosol receptor of rabbit uterus.

Authors:  G A Chernayaev; T I Barkova; V V Egorova; I B Sorokina; S N Ananchenko; G D Mataradze; N A Sokolova; V B Rozen
Journal:  J Steroid Biochem       Date:  1975 Nov-Dec       Impact factor: 4.292

Review 2.  X-ray conformation of some estrogens and their binding to uterine receptors.

Authors:  M Hospital; B Busetta; C Courseille; G Precigoux
Journal:  J Steroid Biochem       Date:  1975 Mar-Apr       Impact factor: 4.292

3.  The relationship between estrogenic action and chemical constitution in a group of azomethine derivatives.

Authors:  H H KEASLING; F W SCHUELER
Journal:  J Am Pharm Assoc Am Pharm Assoc       Date:  1950-02

4.  Diethylstilbestrol metabolites and analogs. New probes for the study of hormone action.

Authors:  K S Korach; M Metzler; J A McLachlan
Journal:  J Biol Chem       Date:  1979-09-25       Impact factor: 5.157

5.  Displacement of estradiol from estrogen receptors by simple alkyl phenols.

Authors:  G C Mueller; U H Kim
Journal:  Endocrinology       Date:  1978-05       Impact factor: 4.736

6.  Molecular structures of metabolites and analogues of diethylstilbestrol and their relationship to receptor binding and biological activity.

Authors:  W L Duax; D C Swenson; P D Strong; K S Korach; J McLachlan; M Metzler
Journal:  Mol Pharmacol       Date:  1984-11       Impact factor: 4.436

7.  Metabolic fate of diethylstilbestrol in the Syrian golden hamster, a susceptible species for diethylstilbestrol carcinogenicity.

Authors:  R Gottschlich; M Metzler
Journal:  Xenobiotica       Date:  1980-05       Impact factor: 1.908

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.